1 Table of Contents

2 Introduction

3 Products under Development

• 3.1 Positron Emission Tomography (PET) Systems - Pipeline Products by Stage of Development
• 3.2 Positron Emission Tomography (PET) Systems - Pipeline Products by Territory
• 3.3 Positron Emission Tomography (PET) Systems - Pipeline Products by Regulatory Path
• 3.4 Positron Emission Tomography (PET) Systems - Pipeline Products by Estimated Approval Date
• 3.5 Positron Emission Tomography (PET) Systems - Ongoing Clinical Trials

4 Positron Emission Tomography (PET) Systems - Pipeline Products under Development by Companies

• 4.1 Positron Emission Tomography (PET) Systems Companies - Pipeline Products by Stage of Development
• 4.2 Positron Emission Tomography (PET) Systems - Pipeline Products by Stage of Development

5 Positron Emission Tomography (PET) Systems Companies and Product Overview

• 5.1 Brain Biosciences Inc Company Overview
• 5.2 General De Equipment for Medical Imaging SA Company Overview
• 5.3 Jagiellonian University Company Overview
• 5.4 Lightpoint Medical Ltd Company Overview
• 5.5 Nuclear, Plasma, and Radiological Engineering Company Overview
• 5.6 Philips Healthcare Company Overview
• 5.7 Positrigo AG Company Overview
• 5.8 Ray Vision Intl Corp. Company Overview
• 5.9 Stanford University Company Overview
• 5.10 SynchroPET Company Overview
• 5.11 University of Washington Company Overview
• 5.12 West Virginia University Company Overview

6 Positron Emission Tomography (PET) Systems- Recent Developments

7 Appendix

Positron Emission Tomography (PET) Systems - Medical Devices Pipeline Assessment, 2020

Summary

GlobalData's Medical Devices sector report, “Positron Emission Tomography (PET) Systems - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Positron Emission Tomography (PET) Systems pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Positron Emission Tomography (PET) Systems scan is an imaging test that helps reveal how your tissues and organs are functioning. A PET scan uses a radioactive drug (tracer) to show this activity. The tracer may be injected, swallowed or inhaled, depending on which organ or tissue is being studied by the PET scan.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Positron Emission Tomography (PET) Systems under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Positron Emission Tomography (PET) Systems and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to Buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Positron Emission Tomography (PET) Systems under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date